ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EVG Evgen Pharma Plc

0.875
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.875 0.85 0.90 0.875 0.875 0.88 0.00 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.59 2.39M
Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.88p. Over the last year, Evgen Pharma shares have traded in a share price range of 0.85p to 4.05p.

Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £2.39 million. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.59.

Evgen Pharma Share Discussion Threads

Showing 801 to 825 of 13000 messages
Chat Pages: Latest  40  39  38  37  36  35  34  33  32  31  30  29  Older
DateSubjectAuthorDiscuss
07/11/2018
13:14
FWIW am now a holder here. The 95k trade yesterday was mine. Looked like a good double bottom and news due in next few weeks.
sicilian_kan
07/11/2018
12:58
This is about to explode, quoted 23p to buy £10,000 worth. No stock left!
spmc
07/11/2018
12:48
Good to see the price drifting up on relatively low volume. We are almost bound to see further strength ahead of the trial results at the end of the year IMHO.

Onwards and upwards!

Nobby

nobbygnome
04/11/2018
17:53
Who cares ?I asked for your help as shafted by an Aim Director and you left me in lurch So much for helping Pi vs Aim corruption.
nico115
04/11/2018
15:17
Evgen Pharma present at our growth company seminar in Manchester on the 20th November which may be of interest to shareholders or potential investors.
sharesoc
01/11/2018
06:50
I also bought stock here 200 shares I'm sure the twitter gang will get these to 20p at least ..last time 27p pre trial results !!Shop broker has a 113p from memory Strong buy Target 30p
nico115
29/10/2018
09:49
Just bought another 25k ahead of the trial results at the end of the year. Yes I know there are the fundraising shares to clear but not all of them will be finding their way on to the market. I am confident of a rise in price towards the end of the year and 13.5p seems a bargain price to me!
nobbygnome
24/10/2018
11:21
Interesting research on Sulforaphane and Triple Negative Breast Cancer;

Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells



"The combination of sulforaphane and doxorubicin displayed a greater inhibitory effect on MDA-MB-231 xenografts growth as compared to either treatment alone."

We should get the results of our study in this area using SFX-01 in the next couple of months.

pdt
18/10/2018
20:13
I hate these placings, we won’t see any rise before the results now. These placings create an such a big overhang that drag down the price. With how low the volume is here there’s no way it will be cleared before the results :(
spmc
18/10/2018
13:08
If they have a positive result from either phase II it strengthens their hand in negotiations. Personally I am happy with the small raise.
pdt
18/10/2018
10:57
This is not really comparable with IMM but the size of the raise is a big concern... enough to cover 'a few months' after the pII trial is very short term planning and either suggests a lack of confidence in or by the bod, or they are banking on a serious collaboration deal that answers even the medium term funding needs.This doesn't fill me with confidence, continue to watch but I've removed my buy-in alert and will trade post the next RNS.
rathean
18/10/2018
09:34
;-) Just unable to check on the move

Ps thanks for the info

sicilian_kan
18/10/2018
08:57
s-k - lazy sod ;¬) Cancer is, stroke isn't.
supernumerary
18/10/2018
08:19
Agreed. Not much of an insurance policy though in this case.

Out of interest are the trials open label?

Supernumerary - you make a good point.

sicilian_kan
18/10/2018
08:17
Great Level to buy stockThis always runs up to trial results With the most important ones in December this will run up to 20pEspecially if the twitter gang bought in this placing !!
nico115
18/10/2018
08:12
Interims are due start of December - I don't know their cash position, but it's possible auditors are fretting about a going concern statement unless they have more cash in the kitty. I took the IMM fund raising as a big red card but I'm not sure the same applies here.
supernumerary
18/10/2018
07:42
s_k

Agreed. Not sure quite what to think. As an investor you wonder why they didnt wait until the anticipated good results are announced. However, as with IMM I guess it is an insurance policy.

On the bright side for those looking to get in ahead of the trial results the price is now lower!

nobbygnome
18/10/2018
07:38
Odd time and price for a placing. A watcher not a holder here.
sicilian_kan
16/10/2018
13:18
Seems very quiet here especially since there should be a flurry of news over the next 3 or 4 months;

Results expected from two Phase IIs and some pre-clinical news in particular Kings / Ischemic Stroke, Christies / Triple Negative Breast Cancer and Autism / Kings. Good chance of a licence deal from one of those two trials if they are positive.

The risk/reward seems good to me for company with a market cap of £15m.

There are of course negatives, we have seen what happens when small caps have disappointing trial results. And the cash must be tight now.

On balance I have been adding.

pdt
08/10/2018
16:36
>> btfd497

Your post deserves a reply from someone! Results from both the the SAH and breast cancer trial are due around the end of the year. Since we had positive interim results from the breast cancer trial and the lead investigator was very confident at the investor day recently, it would be extremely surprising if the final trial results weren't positive enough for the drug to proceed. The SAH trial is more difficult to predict but there is a high unmet need if it is successful.

So IMHO the price is bound to rise ahead of the year end and I am beginning to put more money where my mouth is. If you are of a slightly nervous disposition, it would be certainly worth selling some ahead of the results if that rise does indeed happen.

Of course just IMHO and you should DYOR.....

Nobby

nobbygnome
08/10/2018
10:56
I bought in at 21p back in early May and have been patiently waiting for the tides to turn as currently 25%down.

I have two different options which I’m looking at.
1. Cut my losses and invest my £ elsewhere.
2. Double down to lower my average buy in.

I don’t want to make any rash decisions so that’s why I’m asking the board... When are we likely to hear results etc. What sort of price could this go to if the results are good.
Thanks :)

btfd497
26/9/2018
08:04
It's great to have some rational discussion on a thread for a change! It is a shame that people like francisgalton turn up to deliberately try to trash it.

There is clear value here both short and medium term.

nobbygnome
26/9/2018
07:40
Thanks nobby, timbo and pdt for the helpful information.

So in summary, the core sulforaphane patents expire in 2028, however:
- they have manufacturing and isolation / stabilisation patents to 2033
- they have data exclusivity (another company would have to replicate their preclinical and trial data and not rely on it) which is a significant hurdle to entry, for 10 years once approved, in Europe, and 7 years in orphan only conditions in the US.
- there are analogues with patents to 2033 which appear to be better for oncology but which are not expected to be better for subarachnoid haemorrhage and other neurological indications.

So not ideal, but there does on the face of it appear to be enough protection to ensure Evgen can generate value.

sicilian_kan
24/9/2018
10:48
In addition to those patents there are Analogues granted running from 2013. Some of these have been tested and shown to have better properties in respect of cancer treatment than SFX-01.
pdt
24/9/2018
07:09
See SFX-01 IP-schedule below. Patents generally expire 20 years after filing, but there are several forms of patent extension and marketing exclusivity extension which normally apply.

For example, in the EU there is a 10 years exclusivity period (no cross referral to innovator’s regulatory data), plus one extra year if there is a new indication added since the original licence approval:


In the US drugs with orphan indications are granted 7 year exclusivity (i.e. SFX-01 for SAH)







From:

timbo003
Chat Pages: Latest  40  39  38  37  36  35  34  33  32  31  30  29  Older

Your Recent History

Delayed Upgrade Clock